{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:52:25Z","timestamp":1764874345914,"version":"3.46.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA233465"],"award-info":[{"award-number":["U54CA233465"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA233396"],"award-info":[{"award-number":["U54CA233396"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA0233444"],"award-info":[{"award-number":["U54CA0233444"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic advancements and rapid development of treatment resistance. Fatty acid-conjugated gemcitabine analogs have shown improved antitumor efficacy. This study investigates the effects of gemcitabine conjugated with caprylic acid (Gemcitabine-8C) in combination with AZD 1775, a WEE1 inhibitor, using patient-derived PDAC organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient-derived PDAC cells (G43, G46) were cultured in a gelatin-based 3D organoid system with tunable stiffness to mimic the tumor microenvironment. Cells were treated with gemcitabine, Gemcitabine-8C, AZD 1775, or their combination. The study assessed treatment efficacy, extracellular matrix influence, morphology, gene expression, and drug resistance mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combination of AZD 1775 and Gemcitabine-8C significantly enhanced treatment efficacy compared to monotherapies or gemcitabine with AZD 1775. G43 cells were more sensitive to treatment than G46. Increased matrix stiffness correlated with greater drug resistance. Resistant cells exhibited elevated oxidative stress, while sensitive cells showed F-actin structural alterations absent in resistant counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AZD 1775 enhances the efficacy of Gemcitabine-8C at non-toxic doses, demonstrating its potential for overcoming PDAC treatment resistance. The cell origin and tumor microenvironment plays a key role in modulating drug response, highlighting the need for microenvironment and individualized-targeted strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0326550","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:43:32Z","timestamp":1764873812000},"page":"e0326550","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6759-6834","authenticated-orcid":true,"given":"Jonathan","family":"Barajas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Agyare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saun-Joo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"8","key":"pone.0326550.ref001","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"CJ Halbrook","year":"2023","journal-title":"Cell"},{"year":"2025","author":"Society, A. C","key":"pone.0326550.ref002"},{"issue":"2","key":"pone.0326550.ref003","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"AK Beutel","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"issue":"10","key":"pone.0326550.ref004","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3390\/cancers14102486","article-title":"Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review","volume":"14","author":"T Koltai","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0326550.ref005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12885-023-10928-w","article-title":"Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer","volume":"23","author":"A Inkoom","year":"2023","journal-title":"BMC Cancer"},{"key":"pone.0326550.ref006","doi-asserted-by":"crossref","first-page":"642328","DOI":"10.3389\/fonc.2021.642328","article-title":"WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma","volume":"11","author":"SJ Hartman","year":"2021","journal-title":"Front Oncol"},{"issue":"13","key":"pone.0326550.ref007","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","article-title":"WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe","volume":"17","author":"PC De Witt Hamer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"pone.0326550.ref008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fphar.2019.00864","article-title":"Wee1 inhibitor AZD1775 effectively inhibits the malignant phenotypes of esophageal squamous cell carcinoma in vitro and in vivo","volume":"10","author":"S Bi","year":"2019","journal-title":"Front Pharmacol"},{"issue":"22","key":"pone.0326550.ref009","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1080\/15384101.2017.1301329","article-title":"AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells","volume":"16","author":"PJ Webster","year":"2017","journal-title":"Cell Cycle"},{"issue":"3","key":"pone.0326550.ref010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/cancers12030719","article-title":"Wee1 inhibition enhances the anti-tumor effects of capecitabine in preclinical models of triple-negative breast cancer","volume":"12","author":"TM Pitts","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0326550.ref011","article-title":"Tumor bioengineering using a transglutaminase crosslinked hydrogel","volume":"9","author":"JY Fang","year":"2014","journal-title":"PLoS One"},{"key":"pone.0326550.ref012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"MM Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"pone.0326550.ref013","doi-asserted-by":"crossref","first-page":"103730","DOI":"10.1016\/j.dnarep.2024.103730","article-title":"DSB-induced oxidative stress: uncovering crosstalk between DNA damage response and cellular metabolism","volume":"141","author":"X Li","year":"2024","journal-title":"DNA Repair (Amst)"},{"issue":"4","key":"pone.0326550.ref014","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers14040916","article-title":"SOX9 triggers different epithelial to mesenchymal transition states to promote pancreatic cancer progression","volume":"14","author":"E Carrasco-Garcia","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"30","key":"pone.0326550.ref015","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1038\/s41388-021-01864-9","article-title":"SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer","volume":"40","author":"J Li","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"pone.0326550.ref016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41419-021-03574-2","article-title":"Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-\u03b21\/SMAD2\/3 pathway and ABCC1 transactivation","volume":"12","author":"L Wei","year":"2021","journal-title":"Cell Death Dis"},{"issue":"2","key":"pone.0326550.ref017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/biom11020212","article-title":"Role of small GTPase RhoA in DNA damage response","volume":"11","author":"C Cheng","year":"2021","journal-title":"Biomolecules"},{"issue":"18","key":"pone.0326550.ref018","doi-asserted-by":"crossref","first-page":"25377","DOI":"10.18632\/oncotarget.8298","article-title":"Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations","volume":"7","author":"V Sharma","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"pone.0326550.ref019","doi-asserted-by":"crossref","first-page":"108307","DOI":"10.1016\/j.jbc.2025.108307","article-title":"Anaplerosis by medium-chain fatty acids through complex interplay with glucose and glutamine metabolism","volume":"301","author":"HM German","year":"2025","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0326550.ref020","article-title":"Development and characterization of a Wee1 kinase degrader","volume":"27","author":"Z Li","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"8","key":"pone.0326550.ref021","doi-asserted-by":"crossref","first-page":"114606","DOI":"10.1016\/j.celrep.2024.114606","article-title":"GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer","volume":"43","author":"AP Drainas","year":"2024","journal-title":"Cell Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:43:37Z","timestamp":1764873817000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326550"}},"subtitle":[],"editor":[{"given":"Filomena","family":"de Nigris","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326550","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}